The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Recent evidence points to Myc--a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers--as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy cells. Here we report on the action mechanism of...
Guardado en:
Autores principales: | Mauro Savino, Daniela Annibali, Nicoletta Carucci, Emilia Favuzzi, Michael D Cole, Gerard I Evan, Laura Soucek, Sergio Nasi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/87fb9854901348e2bd4e187527a28c7e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MYC-type transcription factors, MYC67 and MYC70, interact with ICE1 and negatively regulate cold tolerance in Arabidopsis
por: Masaru Ohta, et al.
Publicado: (2018) -
MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015) -
TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation
por: Ke Li, et al.
Publicado: (2020) -
ANXA1 (Annexin A1) regulated by MYC (MYC proto-oncogene) promotes the growth of papillary thyroid carcinoma
por: Xiaomei Ying, et al.
Publicado: (2021) -
Inhibition of MYC by the SMARCB1 tumor suppressor
por: April M. Weissmiller, et al.
Publicado: (2019)